Gastrointestinal Market Research Reports & Industry Analysis
While many of these illnesses are chronic and can only be treated medically, more holistic and natural approaches are being used more frequently to prevent and manage gastrointestinal disorders. Many healthcare providers are recommending stress management, a healthy diet, and exercise to prevent and manage symptoms.
Exercise has shown to decrease the risk of colon cancer, minimize constipation and improve overall GI health. Even minimal exercise paired with a healthy diet of fruits, vegetables, low fat protein and avoidance of red meat, animal fat, and processed meats, can go a long way in preventing colon cancer and other GI diseases.
It is known that psychological stress can aggravate symptoms of Crohn’s disease, irritable bowel syndrome, and ulcerative colitis. Taking a mind-body approach to health can help these patients manage their illnesses. Techniques such as yoga, meditation, massage, and acupuncture can lower stress and in turn reduce bowel symptoms. Doctors also recommend an anti-inflammatory diet (omega-3 fatty acids, fruits & vegetables, and protein rich food like fish, chicken and soy) for people suffering from Crohn’s disease.
Gastrointestinal Industry Research & Market Reports
-
The 2026-2031 World Outlook for Dysphagia Management
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Gastrointestinals
... millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project ... Read More
-
The 2026-2031 World Outlook for Gastrointestinal Bleeding Treatments
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Digestive Remedies
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Helicobacter Pylori Diagnostics
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
Global Gastrointestinal Diseases Therapeutics Market 2025-2029
... diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market ... Read More
-
OTC Consumer Health Market, By Product Type (Dermatological Products, Vitamins & Dietary Supplements, Wound Care Management Products, Gastrointestinal Products, Ophthalmology products, Others), By Distribution Channel (Online Stores, Offline Stores, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... OTC health products may help to manage recurring problems such as migraines and allergies. They are safe and effective when followed as directed by the directions on the label and as directed by a healthcare ... Read More
-
Global Gastrointestinal Stromal Tumors Therapeutics Market 2025-2029
... the gastrointestinal stromal tumors therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding ... Read More
-
Gastroenterology Market, By Drug Type (Biologics/Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Others), By Dosage Form (Oral, Parenteral, Others), By Disease Type (Inflammatory Bowel Diseases (IBD), Crohn\\\\s Disease, Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)
... gastrointestinal endoscopy devices along with development of novel drugs for gastrointestinal issues can also drive the market growth. Various market players are engaged in new product launches and expansions to cater to increasing needs of ... Read More
-
Inflammatory Bowel Disease (IBD) Therapeutics
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. TNF inhibitors, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 Billion ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More
-
Digestive Enzyme Supplements
... at a CAGR of 5.9% over the analysis period 2024-2030. Additional Supplements, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$1.2 Billion by the end of ... Read More
-
Antacids
... 2.2% over the analysis period 2024-2030. Proton Pump Inhibitors, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$2.2 Billion by the end of the analysis period. ... Read More
-
Digestive Health Supplements
... at a CAGR of 5.0% over the analysis period 2024-2030. Prebiotics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$17.0 Billion by the end of the ... Read More
-
Gastrointestinal Videoscopes
... CAGR of 6.4% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$5.3 Billion by the end of the analysis period. ... Read More
-
Irritable Bowel Syndrome (IBS) Therapeutics
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. IBS-D, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.9 Billion by ... Read More
-
Gastrointestinal (GI) Endoscopy Devices
... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$25.5 ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.6 Billion by ... Read More
-
Constipation Treatment
... CAGR of 5.9% over the analysis period 2024-2030. Laxatives, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$12.3 Billion by the end of the analysis period. ... Read More
-
Gastrointestinal Stents
... CAGR of 5.9% over the analysis period 2024-2030. Biliary Stents, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$382.2 Million by the end of the analysis ... Read More
-
Ulcerative Colitis Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$5.6 Billion by the end of the ... Read More
-
Short Bowel Syndrome (SBS)
... 2030, growing at a CAGR of 21.6% over the analysis period 2024-2030. GLP-2, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.4 Billion by the end ... Read More
-
Peptic Ulcer Drugs
... at a CAGR of 2.2% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Bilirubin Meters
... CAGR of 6.8% over the analysis period 2024-2030. Benchtop, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the end of the analysis period. ... Read More
-
Bariatric (Obesity) Surgical Devices
... 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Sleeve Gastrectomy, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$3.6 Billion by the ... Read More